DE69838025D1 - Chinazolinone die farnesyltransferase hemmen - Google Patents

Chinazolinone die farnesyltransferase hemmen

Info

Publication number
DE69838025D1
DE69838025D1 DE69838025T DE69838025T DE69838025D1 DE 69838025 D1 DE69838025 D1 DE 69838025D1 DE 69838025 T DE69838025 T DE 69838025T DE 69838025 T DE69838025 T DE 69838025T DE 69838025 D1 DE69838025 D1 DE 69838025D1
Authority
DE
Germany
Prior art keywords
6alkyl
6alkyloxy
hydrogen
halo
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838025T
Other languages
English (en)
Other versions
DE69838025T2 (de
Inventor
Patrick Rene Janssen Angibaud
Marc Gaston Janss Venet
Eddy Jean Freyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69838025D1 publication Critical patent/DE69838025D1/de
Application granted granted Critical
Publication of DE69838025T2 publication Critical patent/DE69838025T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69838025T 1997-04-25 1998-04-17 Chinazolinone die farnesyltransferase hemmen Expired - Lifetime DE69838025T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201259 1997-04-25
EP97201259 1997-04-25
PCT/EP1998/002357 WO1998049157A1 (en) 1997-04-25 1998-04-17 Farnesyltransferase inhibiting quinazolinones

Publications (2)

Publication Number Publication Date
DE69838025D1 true DE69838025D1 (de) 2007-08-16
DE69838025T2 DE69838025T2 (de) 2008-05-08

Family

ID=8228267

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838025T Expired - Lifetime DE69838025T2 (de) 1997-04-25 1998-04-17 Chinazolinone die farnesyltransferase hemmen

Country Status (22)

Country Link
US (2) US6177432B1 (de)
EP (1) EP0977750B1 (de)
JP (1) JP4308919B2 (de)
KR (1) KR100520401B1 (de)
CN (1) CN1094937C (de)
AT (1) ATE366250T1 (de)
AU (1) AU738628B2 (de)
BR (1) BR9809398A (de)
CA (1) CA2288140C (de)
CZ (1) CZ296959B6 (de)
DE (1) DE69838025T2 (de)
ES (1) ES2289783T3 (de)
HU (1) HUP0001122A3 (de)
IL (1) IL130363A (de)
NO (1) NO317576B1 (de)
NZ (1) NZ336233A (de)
PL (1) PL190944B1 (de)
RU (1) RU2205831C2 (de)
SK (1) SK146199A3 (de)
TR (1) TR199902606T2 (de)
WO (1) WO1998049157A1 (de)
ZA (1) ZA983504B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100520401B1 (ko) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
EA003510B1 (ru) 1998-07-06 2003-06-26 Янссен Фармацевтика Н.В. Ингибиторы фарнезилпротеинтрансферазы, применяемые для лечения артропатий
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SI1140935T1 (en) 1998-12-23 2003-10-31 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
KR20010077400A (ko) * 2000-02-02 2001-08-17 성재갑 에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
DE60118889T2 (de) * 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
CA2397558A1 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
JP2003525252A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1261342A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren
US20030078281A1 (en) * 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
EP1261343A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit antitumor wirksamen nukleosid-derivaten
WO2001064194A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
EP1267871A2 (de) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit antitumor wirksamen podophyllotoxin-derivaten
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DE60118225T2 (de) * 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
JP4974437B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
EP1322650B1 (de) * 2000-09-25 2008-09-24 Janssen Pharmaceutica N.V. Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
ATE323490T1 (de) * 2000-11-28 2006-05-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
EP1347966B1 (de) * 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
PL208238B1 (pl) 2001-03-12 2011-04-29 Janssen Pharmaceutica Nv Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
US20020177575A1 (en) * 2001-05-04 2002-11-28 Ward Wakeland Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
DE60231646D1 (de) * 2001-12-19 2009-04-30 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
FR2837201A1 (fr) * 2002-03-18 2003-09-19 Servier Lab Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1655289A1 (de) * 2004-11-04 2006-05-10 Embl Quinazoline Derivate, Prozess zu deren Herstellung , deren Verwendung als Antimitotika sowie diese beinhaltende pharmazeutische Zusammensetzunegen
PL2362218T3 (pl) 2004-11-05 2015-02-27 Janssen Pharmaceutica Nv Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP1968591A4 (de) 2005-12-23 2010-02-17 Link Medicine Corp Behandlung von synucleinopathien
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2021335B1 (de) 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclische verbindungen als c-fms-kinasehemmer
UA93085C2 (en) 2006-04-20 2011-01-10 Янссен Фармацевтика Н.В. Inhibitors of c-fms kinase
JP5256202B2 (ja) 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2370436A1 (de) * 2008-11-13 2011-10-05 Link Medicine Corporation Azachinolinonderivate und deren verwendungen
HRP20171415T4 (hr) * 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
JP6034784B2 (ja) 2010-07-28 2016-11-30 ジャンセン ダイアグノスティックス，エルエルシー ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
JP6359537B2 (ja) 2012-08-07 2018-07-18 ヤンセン ファーマシューティカ エヌ．ベー． 複素環エステル誘導体の調製プロセス
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN103275085B (zh) * 2013-05-30 2015-04-08 温州大学 一种喹唑啉并喹唑啉酮化合物及其合成方法和用途
EP3385395B9 (de) * 2015-08-17 2020-05-20 Kura Oncology, Inc. Verfahren zur behandlung von krebspatienten mit farnesyl-transferase-inhibitoren
WO2018085518A2 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
US5646154A (en) * 1992-10-07 1997-07-08 Sumitomo Pharmaceuticals Co., Ltd. Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
KR100520401B1 (ko) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논

Also Published As

Publication number Publication date
JP4308919B2 (ja) 2009-08-05
JP2001522364A (ja) 2001-11-13
ZA983504B (en) 1999-10-25
CZ296959B6 (cs) 2006-08-16
HUP0001122A2 (hu) 2001-04-28
TR199902606T2 (xx) 2000-07-21
CN1094937C (zh) 2002-11-27
AU7646098A (en) 1998-11-24
CA2288140C (en) 2007-04-03
NZ336233A (en) 2001-01-26
IL130363A (en) 2002-08-14
WO1998049157A1 (en) 1998-11-05
IL130363A0 (en) 2000-06-01
CA2288140A1 (en) 1998-11-05
KR100520401B1 (ko) 2005-10-12
NO995169L (no) 1999-12-27
ES2289783T3 (es) 2008-02-01
US6358961B1 (en) 2002-03-19
PL190944B1 (pl) 2006-02-28
NO995169D0 (no) 1999-10-22
AU738628B2 (en) 2001-09-20
KR20000069560A (ko) 2000-11-25
NO317576B1 (no) 2004-11-15
EP0977750A1 (de) 2000-02-09
EP0977750B1 (de) 2007-07-04
DE69838025T2 (de) 2008-05-08
PL336468A1 (en) 2000-06-19
RU2205831C2 (ru) 2003-06-10
CN1252800A (zh) 2000-05-10
ATE366250T1 (de) 2007-07-15
US6177432B1 (en) 2001-01-23
CZ371799A3 (cs) 2000-02-16
HUP0001122A3 (en) 2002-03-28
SK146199A3 (en) 2000-06-12
BR9809398A (pt) 2000-06-13

Similar Documents

Publication Publication Date Title
DE69838025D1 (de) Chinazolinone die farnesyltransferase hemmen
NO994268D0 (no) Farnesyltransferase-inhiberende 1,8-annelerte kinolinonderivater substituert med N- eller C-bundede imidazoler
TW349948B (en) Farnesyl transferase inhibiting 2-quinolone derivatives
MY114444A (en) Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl -2-quinolone derivatives
BG105631A (en) 1,2-annelated quinoline derivatives
CA2290992A1 (en) (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
YU65802A (sh) Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
SE0102315D0 (sv) Compounds
YU19002A (sh) Derivati hinolil-propil-piperidina, njihovo dobivanje i smeše koje ih sadrže
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ES480426A1 (es) Procedimiento para la obtencion de hidroxipropil-imidazoles.
IL99471A0 (en) Pharmaceutical compositions containing pyridylmethylsulphinyl-1h-benzimidazole derivatives as active ingredient therein
NO964216L (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
SE9704770D0 (sv) New use
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
MXPA04003158A (es) Compuestos de carboniloxi-cianometilo cmo agentes.
MY118312A (en) Angiogenesis inhibiting 5- substituted- 1,2,4- thiadiazolyl derivatives
AR026285A1 (es) Profarmacos de higromicina a
TH28677B (th) ฟาร์เนซิลทรานสเฟอเรสที่ยับยั้งอนุพันธ์ของ 2-ควิโนโลน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition